ConductScience.org, home

Paper95205

Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity.

Herberman RR and 2 others. Nature, 1979. Cited by 572 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Papers, record 95205. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/95205

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity.
PubMed
Journal
Nature
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
572
iCite
Relative citation ratio, by iCite
16.8
iCite
Revised in PubMed
2019-06-17
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Herberman RRR R
2Ortaldo JRJ R
3Bonnard GDG D

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibody-Dependent Cell CytotoxicityMajor topic
Cytotoxicity, ImmunologicMajor topic
Immunity, InnateMajor topic
InterferonsMajor topic
Antigen-Antibody Reactions
Humans
Killer Cells, Natural

Source PubMed

Cited by111

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 572 citations.

PMIDTitleJournalYearIn PapersSource
37,456,846CSL362 potently and specifically depletes pDCs invitro and ablates SLE-immune complex-induced IFN responses.iScience2023https://conductscience.org/library/papers/37456846PubMed
35,931,666Reactive oxygen species-responsive and Raman-traceable hydrogel combining photodynamic and immune therapy for postsurgical cancer treatment.Nat Commun2022https://conductscience.org/library/papers/35931666PubMed
35,466,184
Prompt Hematological Recovery in Response to a Combination of Pegylated Interferon α-2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks of Rapid Immune Reconstitution.
Hematol Rep2022https://conductscience.org/library/papers/35466184PubMed
35,327,405Influence of Fetomaternal Microchimerism on Maternal NK Cell Reactivity against the Child's Leukemic Blasts.Biomedicines2022https://conductscience.org/library/papers/35327405PubMed
33,304,763Engineering Prodrug Nanomedicine for Cancer Immunotherapy.Adv Sci (Weinh)2020https://conductscience.org/library/papers/33304763PubMed
31,798,59629-Color Flow Cytometry: Unraveling Human Liver NK Cell Repertoire Diversity.Front Immunol2019https://conductscience.org/library/papers/31798596PubMed
30,932,943Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.Melanoma Res2019https://conductscience.org/library/papers/30932943PubMed
30,531,990In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment.Nat Nanotechnol2019https://conductscience.org/library/papers/30531990PubMed
29,577,477Neutrophil-Based Drug Delivery Systems.Adv Mater2018https://conductscience.org/library/papers/29577477PubMed
29,213,274Natural Killer Cells in Antifungal Immunity.Front Immunol2017https://conductscience.org/library/papers/29213274PubMed
28,928,751"Multi-Omics" Analyses of the Development and Function of Natural Killer Cells.Front Immunol2017https://conductscience.org/library/papers/28928751PubMed
24,188,121Human immune responses to Plasmodium falciparum infection: molecular evidence for a suboptimal THαβ and TH17 bias over ideal and effective traditional TH1 immune response.Malar J2013https://conductscience.org/library/papers/24188121PubMed
24,154,599Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry.Sci Transl Med2013https://conductscience.org/library/papers/24154599PubMed
19,276,249The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.Clin Cancer Res2009https://conductscience.org/library/papers/19276249PubMed
17,675,184Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.Vaccine2007https://conductscience.org/library/papers/17675184PubMed
9,536,127Cathepsin G enhances human natural killer cytotoxicity.Immunology1998https://conductscience.org/library/papers/9536127PubMed
9,203,979Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15.Immunology1997https://conductscience.org/library/papers/9203979PubMed
8,705,672Determination of natural killer cell function by flow cytometry.Clin Diagn Lab Immunol1996https://conductscience.org/library/papers/8705672PubMed
8,439,987Mechanism of stimulation of human natural killer cytotoxicity by arabinogalactan from Larix occidentalis.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8439987PubMed
8,439,976Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8439976PubMed

See all 111 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/95205

GET https://conductscience.org/api/papers/v1/95205/cited_by?page=2